1	Home Care Follow up determine the point of inversion of IL-6 levels in			
2	relation to C-Reactive Protein as the cytokine storm marker in COVID-19			
3				
4	Running title			
5				
6	Success of the early and longitudinal markers-based monitoring in			
7	COVID-19			
8				
9	Sérgio Paulo de Mello Mendes Filho ¹ , Fernanda Simão Martins ¹ , Paulo Jose Giroldi ² ,			
10	Raul Honorato e Melo ¹ , Edcleia Lopes de Oliveira ² , Anibal Borin dos Santos ¹ , Dayse			
11	Cristina Oliveira Medeiros ¹ , Sergio de Almeida Basano ³ , Jéssica Amaral Lopes ⁴ , Yury			
12	Oliveira Chaves ^{5,6} , Rebeca Sousa Pinheiro ^{5,6} , Luís Marcelo Aranha Camargo ⁷ , Juliana			
13	Pavan Zuliani ⁴ , Paulo Afonso Nogueira ^{5,6*} ,			
14				
15	1. Serviço de Assistência Médica Domiciliar (SAMD); Secretaria Estadual da Saúde			
16	(SESAU), Av. Gov. Jorge Teixeira, 3734, Industrial, 76821-092, Porto Velho/RO,			
17	Brazil;			
18	2. Laboratório Estadual de Patologia e Análises Clínicas (LEPAC); Av. Gov. Jorge			
19	Teixeira, Industrial, 7245-7385, Porto Velho/RO, Brazil;			
20	3. Hospital Cemetron; Av. Guaporé, 215, Lagoa, 78918-791, Porto Velho/RO, Brazil;			
21	4. Fundação Oswaldo Cruz – Rondonia (FIOCRUZ – RONDONIA); Rua da Beira, 7671,			
22	Lagoa, 76812-245, Porto Velho/RO, Brazil;			
23	5. Instituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz – Amazonas			
24	(FIOCRUZ – AMAZONAS); Rua Terezina, 476, Adrianópolis, 69057-070; Manaus/AM,			
25	Brazil.			

- 26 6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Pedro de Teixeira Ave, Dom
- 27 Pedro, 69040-000, Manaus/AM, Brazil
- 28 7. Instituto de Ciências Biomédicas V (ICB5), Universidade de São Paulo (USP) -
- 29 Campus Monte Negro; Avenida Francisco Prestes Maia, 2728, Setor 2, 76888-000, Monte
- 30 Negro/RO, Brazil;
- 31
- 32 *Corresponding author:
- 33 Paulo Afonso Nogueira, <u>paulo.nogueira@fiocruz.br</u>, cell phone 5592994851620
- 34 Instituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz Amazonas
- 35 (FIOCRUZ AMAZONAS); Rua Terezina, 476 Adrianópolis, 69057-070; Manaus/AM,
- 36 Brazil.
- 37
- 38 Funding:
- 39 Rondônia State Health Department Budget.

40

41

Abstract

43

42

44 The IL-6 has been used for the characterization of the cytokine storm induced by SARS-CoV-2, but so far, no one has found out when and in whom the cytokine 45 storm develops. Our study demonstrates how early and longitudinal clinical-46 based monitoring and dosing of five markers (C-reactive protein, IL-6, fibrinogen, 47 48 ferritin and D-dimer) helped to identify who'd developed the cytokine storm. The peak of IL-6 in pg/mL proportionally higher than the peak of CRP in mg/L was 49 50 sufficient to define the timing of the evolution of cytokine storm syndrome. The 51 administration of antibiotic therapy, anticoagulant therapy and pulse therapy resolved the infection and prevented the progressive deterioration of the lung 52 function of the patients with potential for development of severe COVID-19. 53

54

55 Introduction

The evolution to severe acute respiratory syndrome (SARS) in patients with severe COVID-19 is triggered by a remarkable and uncontrolled lung inflammation characterized by a systemic increase in cytokines and chemokines, known as the macrophage activation syndrome (MAS) or more usually called a "cytokine storm" [1–5]. MAS can directly induce tissue damage, coagulopathy, dyspnea, hypoxemia, hypotension and hemostatic imbalance, which induces a necessity of mechanical ventilation and increases the risk of death [2,3,6–10].

63 A virus-induced cytokine storm includes fever, coagulopathy and immune 64 cell-mediated responses, sharp elevations in acute phase responses [characterized by increases in interleukin 6 (IL-6), ferritin, and C-reactive protein
(CRP)] [9,11–17].

Several studies have addressed that in some cases COVID-19 patients developed MAS similarly to the *hemophagocytic lymphohistiocytosis* (HLH) syndrome [13,18–20]. The HLH is characterized by an exacerbation of innate responses with increases in the CRP levels, ferritin, fibrinogen, D-dimer and interleukin-1 (IL-1) and IL-6 [21]. It is immediately treated via pulse therapy with corticosteroids, anticoagulants, broad-spectrum antibiotics in order to prevent superinfections, and inhibitors of interleukins and immunoglobulins [19,21,22].

Regarding SARS-CoV-2, IL-6 has been used for the characterization of 74 the cytokine storm in severe COVID-19; however, hypoxemia has been the 75 criterion that helps to determine the administration of corticosteroids. Historically, 76 corticosteroids have been effective in immunomodulating hyperinflammation in 77 patients with severe acute respiratory syndrome coronavirus (SARS-CoV) and 78 Middle East respiratory syndrome coronavirus (MERS-CoV). However, the use 79 of corticosteroids, both in COVID-19 and in the SARS and MERS epidemics, has 80 81 become a great conundrum, since the early use led to adverse consequences such increased viral load and worsening of the disease, but when properly 82 administered, corticosteroids lead to an amelioration, such as reduction of fever, 83 improvement of oxygenation and reduction of mortality rate [2,23,24]. Even so, 84 the appropriate timing and dosage for their administration still represent a 85 dilemma in which there is a choice between uncontrolled viral infection versus 86 87 reduced progressive deterioration of oxygenation indicators, rapid imaging progress and excessive inflammatory response [23,25]. 88

Thrombotic complications are also an important issue in COVID-19 [26-89 90 331. Clinical and laboratory findings of COVID-19 patients included elevated D-dimer, prolonged prothrombin time, and thrombocytopenia, 91 disseminated intravascular coagulation [33,34]. In addition, elevated D-dimer 92 levels and hyperfibrinogenemia were used as criteria for the application of an 93 aggressive thromboprophylaxis [31]. Still, co-infections involving respiratory 94 bacteria and viruses are commonly identified as important causes of morbidity 95 and mortality [35,36]. In COVID-19, secondary bacterial infections are more 96 common than co-infections, especially in patients developing severe COVID-19 97 98 [37]. CRP is often used as a solution for a clinical dilemma. Although it is an acute phase protein in response to inflammation, it is the only point-of-care biomarker 99 of bacterial infection used to determine antibiotic treatment in patients with acute 100 101 respiratory infections as well as for monitoring antibiotic treatment in patients with known bacterial infections and for differentiating between bacterial and viral 102 103 infections in various clinical situations [38-41].

104 In the present study, we will demonstrate how the early and longitudinal monitoring clinical-based practice, as well as quantifying 5 markers (CRP, IL-6, 105 106 fibrinogen, ferritin, D-dimer) daily has served to reduce the rates of mortality due to COVID-19 among the health professionals from Porto Velho, the capital of the 107 Rondônia state. This longitudinal follow-up of inflammatory markers subclassified 108 patients among those who needed only antibiotic therapy (defined here as 109 110 YELLOW PATIENT); those in which antibiotic therapy and anticoagulant therapy 111 were sufficient for resolution of COVID-19 (RED PATIENT); and the third group in which COVID-19 evolved into a severe disease (PURPLE PATIENT), and for 112 which antibiotic therapy, anticoagulant therapy and pulse therapy administration 113

resolved the infection and prevented the progressive deterioration of lung injury.
To this end the observation of CRP and IL-6 kinetics levels can be markers to
distinguish the timing of the cytokine storm in patients with a more severe form of
COVID-19 in relation that one that presented COVID-19 with endothelial injury
determining the therapy to be conduct.

119

Materials and Methods

121 COVID-19 severity early identification plan

The state of Rondônia instituted the Home Medical Care Service (HMCS) 122 more than 10 years ago to treat patients with chronic diseases via home care, to 123 124 relieve overcrowding the public hospitals in the state network. With the 125 emergence of the SARS-CoV-2 pandemic, this service was intensified in view of the high mortality rates of health professionals due to fight against COVID-19. 126 The principal goal was the early identification of cases followed by a severity 127 128 analysis and follow-up based on daily monitoring of clinical-laboratory parameters to assess the patient's vulnerability potential. This follow-up was carried out by 129 the HMCS and consisted of a nursing team responsible for blood sample 130 collection, monitoring of vital signs and medicine administration when necessary, 131 and a medical remote health team that, when necessary, included a physical visit. 132 133 The Rondonia State Laboratory of Pathology and Clinical Analysis (LEPAC) supplied the kits for measure the markers used for the follow-up of the patients. 134 The State Coordinating Office for Management and Pharmaceutical Assistance 135 136 carried out the provision of supplies and medicines to avoid shortages and enable an uninterrupted flow of administration to the patients. Laboratory tests wereperformed daily by LEPAC.

139

140 Clinical and laboratory monitoring of patients with COVID19

Health professionals as well as military personnel and their respective 141 142 family members were referred to the Oswaldo Cruz Polyclinic (OCP) where they 143 were submitted to a medical evaluation and diagnoses of SARS-CoV-2 infection 144 by RT-PCR, via intranasal swab sample collection, or rapid serological test. There 145 was a total of 8,902 visits to the Oswaldo Cruz Polyclinic (OCP) in the period from 2nd June 2020 to 31st December 2020. Of this, 631 patients were followed up by 146 HMCS due to clinical laboratory markers alterations. Within this group of patients, 147 we had four deaths. Mortality of patients cared for by the HMCS was 0.045%. 148

The methodology used for the running of HMCS follows: the medical 149 150 evaluation screened the patients for vital signs and the severity of infection. All patients who had no advanced symptoms or signs of clinical deterioration were 151 referred for laboratory markers quantifying at LEPAC. Depending on the results 152 153 of this laboratory markers and the clinical condition, daily follow-up was conducted involved laboratory markers new determinations' when necessary. 154 The treatment was also personalized at home by a HMCS nursing team followed 155 156 by checking vital signs and administering medication. The medical team carried 157 out the remote monitoring and, when necessary, carried out a physical visit.

The study was approved by the Fundação de Medicina Tropical Dr. Heitor Vieira Dourado Ethics Review Board (CAAE: 51963021.9.0000.000) and the requirement for informed consent was waived by the Ethics Commission because these data come from medical and laboratory assistance that took place between
2020 and 2021 and medical records were available anonymously encoded.

163

164 Screening of patients

During the medical consultation, patients who presented signs of clinical 165 166 severity evidenced by a Glasgow score of ≤ 14 , respiratory rate above 24 167 respiratory incursions per minute (RIPM) and O₂ saturation less than 90% were referred for hospitalization to receive therapeutic and ventilatory support or 168 169 admission to the ICU. If the patient had a respiratory rate between 21 and 24 RIPM or alterations in any of the laboratory markers such as CRP, fibrinogen, D-170 171 dimer, ferritin and IL-6, the patient was immediately followed up at home on a personalized and daily basis by the HMCS. 172

173

174 Study population and risk classification

All patients were grouped according to the clinical signs and symptoms and laboratory markers in BLUE, GREEN, YELLOW, RED or PURPLE patient as follows:

BLUE PATIENT: Patients that do not present alterations in laboratory markers
and were classified as having a viral syndrome. All these patients were instructed
to take 10,000 U vitamin D every 48 h due to hypovitaminosis of vitamin D being
described in patients with severe COVID-19 [42]. In addition, 600 mg of
acetylcysteine every 12 h were prescribed due to its glutathione-forming
potential, which protects against oxidation by iNOS [43].

- GREEN PATIENT: characterized as patients that only presented increased 184 185 ferritin levels. For these patients, a therapeutic based on iron metabolism to decrease the uptake and absorption of iron [44] was prescribed, as well as 186 vitamin D and acetylcysteine as mentioned above. The therapy was composed 187 188 of i) 60 mg of chelated zinc as an inhibitor that competes with serum iron ion; ii) proton pump inhibitor 2 h before lunch to control gastric acidity to prevent the 189 190 transformation of ferric ions into ferrous ions absorbed in the intestine; iii) restriction of red meat intake because it is the main source of iron. 191

YELLOW PATIENT: Patients showed elevated CRP in the first examinations,
without increases in fibrinogen. These patients required only antibiotic therapy
and CRP levels served as a guide [41]. If an increase in CRP greater than 5 and
less than 20 mg/L, more than 24 RIPM and/or fever, antibiotic therapy with
amoxicillin clavulanate for 7 days was provided. CRP greater than 20 mg/L were
given venous antibiotic therapy with amoxicillin clavulanate with levofloxacin or
oral doxycycline.

RED PATIENT: Include the ones who presented significant increases in CRP
and IL-6 concomitantly, and principally due to alterations in fibrinogen. These
patients received antibiotic therapy with amoxicillin clavulanate and 1 mg/kg/day
of enoxaparin. They were characterized as having a severe endothelial lesion
due to increased fibrinogen even after 1 mg/kg/day of enoxaparin for more than
48 h.

PURPLE PATIENT: Initially all were classified as RED PATIENTS but evolved
to cytokine storm syndrome. Some of them responded with alterations in CRP,
ferritin, and IL-6, in addition to fibrinogen. Even when after returning to normal
levels, these patients presented proportionally higher IL-6 levels than CRP levels,

which indicated an exacerbation of cytokines, and fibrinogen rose again after a few days. For these patients, in addition to antibiotic coverage, the treatment conducted with 2 mg/kg/day of enoxaparin, deworming with ivermectin to avoid the risk of strongyloidiasis infestation, and pulse therapy with 20 mg dexamethasone on the 1st day followed by 3 days of 10 mg/day and 3 days of 5 mg/day.

215

216 **Results**

217 Subclassification of patients based on follow-up of the five laboratory 218 markers

Six hundred thirty-one patients had clinical laboratory alterations and were 219 220 grouped according to the clinical and laboratory symptoms described above. To demonstrate biochemical and hematological parameters in the first examination 221 a sampling of the total patients was used (Table 1) such as twenty-seven of BLUE 222 223 PATIENT group; twenty-eight of YELLOW PATIENT group; twenty-three of RED PATIENT group and thirty-two of PURPLE PATIENT group. In addition, a group 224 of 27 cases, between 30 and 55 years-old, with a RT-PCR negative diagnosis of 225 COVID-19 and no symptoms was recruited to be followed up as a CONTROL 226 227 group. The analysis did not show differences between patients belong to either 228 YELLOW, RED or PURPLE groups, little changes in the neutrophil/lymphocyte ratio and in TGO and TGP levels were observed in PURPLE group. To this end, 229 this first examination follow-up cases with the five laboratory markers was 230 231 important for the subclassified patients.

The YELLOW PATIENT group showed CRP elevations, and the use of 232 233 antibiotics decreased continuously these levels until the baseline (Figure 1A). In these patients, IL-6 levels behaved more timidly and decreased synchronously 234 with CRP levels (Figure 1B). Fibrinogen levels did not exceed the limit of 437 235 mg/dL despite the mild increase in IL-6 levels (Figure 1C) and, therefore, the use 236 of enoxaparin was not necessary. Without increased in fibrinogen levels, there 237 238 was no thrombus formation and, therefore, the D-dimer, a predictor of fibrinolysis, did not increase (Figure 1D). Figure 1E shows the ferritin curve in women. The 239 variation showed that some female patients demonstrated iron metabolism 240 241 disorder, requiring treatment according to the initial protocol. Antibiotic treatment led to decreased CRP and IL-6 levels. Figure 1F demonstrated the ferritin levels 242 in men. In most of the male patients, ferritin levels were much higher than in 243 244 women in the first examination, which is probably due to the eating habits of men. Similarly, the treatment of iron metabolism and control of metabolic syndromes 245 resulted in optimal results, with the decrease of ferritin levels and the reduction 246 of CRP and IL-6 levels concomitantly. These patients had mild to moderate 247 248 clinical symptoms, anosmia, cough, fever, and chest discomfort, and they did not require the oxygen support. 249

Figure 2 represents the behavior of the markers in RED PATIENTs who received venous antibiotic therapy and subcutaneous anticoagulant and evolved to improvements in clinical signs and laboratory results. These patients were treated with 1 mg/kg/day of enoxaparin which resulted in reversal of fibrinogen levels to normal titers. CRP started with higher levels and, when patients were treated with venous antibiotic therapy, they had progressive resolution (Figure 2A). The increase in IL-6 levels accompanied the increases in CRP, but when

CRP levels were below 25 mg/L, with the venous antibiotic therapy there was a 257 258 gradual decrease in IL-6 to normal levels (Figure 2B). In Figure 2C it is possible to observe how increased fibrinogen was used within this protocol as the standard 259 for anticoagulant use (see red arrow). The graph demonstrated that after the 260 increase of fibrinogen levels above 437 mg/dL, the indication of a daily dose of 1 261 mg/kg/day of enoxaparin for nine days was sufficient for the normalization of the 262 263 results. In Figure 2D it is presented the increase in D-dimer levels on the second day of examination demonstrating that these patients had already had previous 264 increases in fibrinogen, since the peak that occurred on the fifth day of 265 266 examinations represented the increase in fibrinogen on the second day (Figure 2C). After this, the D-dimer curve showed that the patient no longer had 267 fibrinolytic activity after anticoagulant therapy. In this group, female patients 268 269 already showed higher levels of ferritin (Figure 2E). Regarding the male patients, most of them also had alterations associated with metabolic syndromes (Figure 270 271 2F).

272 Figure 3 describes the behavior of the markers of patients who underwent an abrupt increase in IL-6 levels, which is the main marker for the characterization 273 274 of a cytokine storm. In Figure 3A, CRP levels in these patients begun with high levels and, after the start of antibiotic therapy, there is a progressive drop. 275 Between sixth-eighth day of illness, in patients with the most severe symptoms, 276 IL-6 levels increased earlier than those of CRP levels, and the peak of IL-6 in 277 pg/mL is proportionally higher than the peak of CRP in mg/L (see thick green 278 279 arrow, Figure 3B). This abrupt increase characterizes the cytokine storm, which 280 was treated with high-dose corticosteroids and resulted in a significant drop in the release of IL-6 until they reach normal levels. This drop is also observed with 281

CRP levels. In Figure 3C, in the graph showing the fibrinogen levels it is clearly 282 283 demonstrated that when the patient was recruited by the service, the patient already presented increased levels of CRP, IL-6 and fibrinogen levels (see thin 284 red arrow), which demonstrates that these patients had already had the disease 285 for several days. The introduction of antibiotic therapy with enoxaparin at 1 mg/kg 286 correlates with the drop of fibrinogen to normal levels, but the sharp increase in 287 IL-6 levels, which denotes a cytokine storm, creates a new increase in fibrinogen 288 levels that is characterized as a second wave, even when using 1 mg/kg of 289 enoxaparin. The re-appearance of an elevation in fibrinogen was an indicator for 290 291 an increase in anticoagulation therapy with enoxaparin of 2 mg/kg day (see blue and red thick arrows, Figures 3A and C). This results in the start of the decrease 292 293 of these markers to normal levels. In Figure 3D, the first increase in D-dimer levels 294 occurred a few days after the peak of fibrinogen levels, around the eighth to tenth day. The new increase in D-dimer occurred on the thirteenth day, which was after 295 296 the second peak of fibrinogen levels that was observed between the eighth to the tenth day (Figure 3C). In Figure 3E, the increase in ferritin levels in female 297 patients shows that these patients have had the disease for some days, and from 298 299 the sixth day, there is an exponential increase and the patient's improvement response is translated into the decrease in the curve. Figure 3F showed the 300 increase in ferritin levels in male patients, with an expected upward and 301 302 progressive curve as can be seen in infections, but around the sixth to seventh day there is a greater than 80% increase in relation to the previous day, 303 demonstrating that ferritin is an excellent marker of inflammatory response. Only 304 patients who developed this abrupt increase compared to the previous day were 305 treated with corticosteroid via pulse therapy. The observation of CRP and IL-6 306

kinetics levels allowed us to distinguish the timing of the cytokine storm in patients
with a more severe form of COVID-19 in relation that one that presented COVID19 with endothelial injury. Although the units of CRP and IL-6 are different, at the
beginning of the disease the kinetics of CRP and IL-6 levels in these two groups
of patients are similar, though with the peak IL-6 in pg/mL being higher than the
peak of CRP in mg/L (Figures 4A and B).

313

Dynamics of laboratory markers in the determination of therapy

315 The dynamics of serological markers allowed us to determine the antibiotic 316 therapy, the anticoagulant therapy, and the administration of pulse therapy. Patients defined as having bacterial co-infection had their infection resolved only 317 with antibiotics. IL-6 and CRP levels served as a guide for the choice of the 318 spectrum of the antibiotics. These patients showed CRP alterations of between 319 5.0 and 20.0 mg/L, and IL-6 up to 30 pg/mL and received antibiotic therapy (ABT) 320 of 875 mg amoxicillin and 125 mg potassium clavulanate every 12 h for 7 days 321 (Figure 5A). Fibrinogen also served as a guide for treatment; if the fibrinogen 322 levels were less than 437 mg/dL, they continued to receive antibiotic therapy. 323 Those patients who had ferritin alterations were also prescribed vitamin D, 324 acetylcysteine and received anti-iron uptake therapy. The other markers were 325 326 unaltered, and the infection was resolved in these patients.

Patients with endothelial injury showed increases in CRP levels to over 20 mg/L and IL-6 up to 30 pg/mL and a concomitant increase in fibrinogen to over 437 mg/dL (Figure 5B). For the opportunistic infection's treatment, ABT was replaced by 1 g of cefepime via venous route and 500 mg clarithromycin via oral

route every 12 h, and patients received 1 mg/kg/day of enoxaparin subcutaneous 331 332 for 7 days. If ferritin levels were high, in addition to vitamin D, acetylcysteine and anti-iron uptake therapy was administered. The patients we also investigated for 333 type 2 diabetes mellitus, hepatic steatosis, and drug hepatitis, in addition to renal 334 function. The infection was resolved with antibiotics and CRP levels were 335 decreased in these patients. Treatment with 1 mg/kg/day of enoxaparin 336 337 decreased fibrinogen in 24 h and therefore there was no increase in D-dimer. Initially, it was not observed patients with increased fibrinogen without increased 338 CRP levels, and this endothelial lesion usually came from a mixed infection. 339 340 Increased fibrinogen production behaved as a marker of the onset of endothelial injury which results from the exposure of tissue factor in the basal membrane 341 (extrinsic via the coagulation cascade with subsequent platelet adhesion). 342

Patients with cytokine storm syndrome showed increased fibrinogen even 343 after 1 mg/kg/day of enoxaparin for more than 48 h and, even when after returning 344 345 to normal levels, fibrinogen levels increase again after a few days (Figure 5C). 346 Unlike patients with endothelial injury, increased fibrinogen occurred concomitantly with CRP, IL-6 and ferritin levels. The follow-up of ferritin was very 347 348 important, since the sharp increase in its values between 70 and 100% of the initial levels together with IL-6 peaks caused an exacerbation of cytokines, 349 indicating macrophage activation syndrome. In addition, patients received 350 therapy to correct metabolic syndrome and iron metabolism. These patients were 351 352 characterized as presenting severe endothelial lesion and the parameters 353 observed guided the treatment of a possible macrophage activation syndrome or even hematophagous lymphohistiocytic syndrome. After deworming with 354 nitazoxanide to avoid the risk of strongyloidiasis infestation, these patients 355

received an increase in the range of coverage of antibiotics, with the addition of meropenem and amikacin, or tazobactam, and the dose of enoxaparin was increased to 2 mg/kg/day, and pulse therapy was conducted with 20 mg of dexamethasone on Day 1, followed by 3 days of 10 mg/day and 3 days of 5 mg/day (Figure 5C).

361

362 **Discussion**

There are no data on the literature demonstrating a home care follow-up 363 364 of markers in COVID-19 patients [23,45,46]. Our study is the first to show a clinical and laboratory follow-up of patients with COVID-19 since the first 365 symptoms conduct in home care. In a sampling of the presentation of COVID-19 366 disease, we observed this heterogeneity from asymptomatic cases to patients 367 who were evolving to SARS, as observed everywhere [3,47–49]. Some patients 368 required oxygen therapy, but daily follow-up prevented worsening and the 369 370 mortality rate was very low. Patients who needed oxygen fell into RED and 371 PURPLE groups. Even with the increase of the markers levels after treatment, only some RED PATIENTS still needed oxygen support. In PURPLE PATIENTs, 372 the computed tomography scans have already showed a high rate of lung 373 374 involvement (personnel communications of clinicians from HMCS) and all patients needed oxygen support. Moreover, the subclassification and monitoring 375 of the markers evaluated allowed us to understand the dynamics of the 376 pathophysiology of SARS in severe COVID-19, which is usually characterized as 377 a cytokine storm [1-5]. We had patients who presented the cytokine storm 378 379 syndrome and, with very rare exceptions; surprisingly none of the patients

evolved for the necessity of mechanical ventilation or were at risk of death, as
commonly observed [2,3,6–10].

The follow-up was completely effective regardless of a first consultation, 382 383 or even without a tomographic image as an effective marker of severity. These observations led us to create a therapeutic protocol associated with the clinical 384 385 picture: CRP as a guide for the introduction of antibiotics, fibrinogen as a guide 386 for the introduction of anticoagulation therapy with enoxaparin and, IL-6 as a guide for the introduction of pulse therapy, which were effective for identifying the 387 cytokine storm [29]. Thus, our greatest finding was that the administration of 388 389 broad-spectrum antibiotic therapy and pulse therapy with dexamethasone and an increased dose of anticoagulant which contributed to resolve the infection of the 390 group of patients who had a COVID-19 of greater severity and were at risk of 391 death. 392

393 Moreover, our study had the opportunity to follow-up all the LEPAC results 394 from the onset of symptoms and the alterations of the evaluated markers gave us clues to the worsening of the disease. The follow-up led us to believe that the 395 markers have a sequence of increases such as: CRP was the first to increase in 396 397 patients without symptoms, and it increased with the onset of symptoms accompanied by IL-6 and ferritin levels. With the use of antibiotic therapy, CRP 398 dropped substantially in the YELLOW PATIENTs with a good therapeutic 399 400 response, improvement in the clinical presentation and laboratory markers in 48 401 h.

402 CRP could be a marker of opsonization at the first sign of a primary 403 bacterial infection, as well as the secondary one resulting from an infectious 404 respiratory viral disease, such as COVID-19 [37,41]. This fact makes us rethink the relationship of CRP with the virus, because CRP would not decrease if it was
only associated with inflammation, whereas the association with high CRP being
most commonly associated with a secondary bacterial infection by respiratory
viruses [38–40,50,51]. Although prescribing broad-spectrum antibiotics is
important for preventing these infections, the use of antibiotics should be prudent
during the evolution of the SARS-CoV-2 pandemic [40,50,52].

411 In RED PATIENTS, CRP and IL-6 levels were already higher even in the first days of infection, though the patients still present mild symptoms; however, 412 fibrinogen increased soon after. After antibiotic and anticoagulant therapy, the 413 414 markers improved with resolution of disease. The increase in fibrinogen due to an even greater increase in CRP and IL-6 levels led to the use of antibiotic 415 therapy and anticoagulant treatment that resolved the infection. Our findings call 416 into question the use of fibrinogen as an early marker of this thrombotic stage, as 417 seen in the H1N1 pandemic [35,36]. According to these studies, colonization of 418 419 the nasopharynx with pathogenic bacteria in respiratory virus infection may 420 predispose patients to a secondary bacterial infection due to impaired mucociliary clearance, thus allowing secondary bacterial invasion, formation of vasculitis 421 422 zones, capillary thrombosis and necrosis around the areas of bronchiolar damage [35,36]. 423

There are no studies on the pathophysiology of endothelial injury for tissue factor exposure in COVID-19. The D-dimer has been considered one of the severity criteria of SARS, suggesting that disseminated intravascular coagulation leads to death in patients with COVID-19 [31,53]. However, D-dimer levels increased late in relation to fibrinogen, therefore, the alterations in fibrinogen observed here were indicative of the dose of anticoagulant needed in the treatment of COVID-19. Thus, alterations in fibrinogen observed here were
resounding in exposing endothelial dysfunction and were indicative of the dose
of anticoagulant needed in the treatment of COVID-19.

433 The PURPLE PATIENTs had behavior similar to RED PATIENT but with high levels markers in the beginning. After antibiotic and anticoagulant therapy, 434 all the markers improved and started to decrease. However, between the ninth 435 436 and tenth day, some patients had an 80% increase in IL-6 levels from the previous day that was accompanied by a sharp increase of CRP. Although the 437 magnitude of IL-6 pg/mL is different in relation to the CRP mg/L, the peak of IL-6 438 439 was earlier and was superior to the peak of CRP (Figure 4). Moreover, these patients had a second wave in fibrinogen evaluation that demanded us to double 440 the dose of the anticoagulant and increase the length of antibiotic therapy in the 441 course of pulse therapy. Thus, our findings bring a new understanding of the 442 sequence of the initial inflammatory response, and no longer place IL-6 as the 443 444 main protagonist, but the inversion of IL-6 levels in relation to CRP for the role to predict the cytokine storm [54-56]. 445

446 The cytokine storm plays an important role in the process of aggravation of the disease and is considered one of the main causes of SARS [1,23,56,57]. 447 IL-6 has been responsible for the characterization of the cytokine storm and MAS 448 in severe COVID-19 [11,23,45,54,58]. Effective suppression of the cytokine storm 449 450 is an important way to prevent the deterioration of patients with severe COVID-19 [59], as has occurred with other epidemics involving SARS, MERS, and severe 451 influenza. The COVID-19 therapy (RECOVERY) randomized controlled and 452 open-label clinical trial showed that use of dexamethasone for up to 10 days 453 resulted in lower mortality over 28 days [60]. The dose used was 6 mg once a 454

day for up to 10 days or until hospital discharge, which is the standard and usual 455 456 care. The effectiveness of the therapy was low and its benefit was apparently only a mere statistical effect [60], while the use of colchicine in adults hospitalized 457 with COVID-19 was worse [61], due likely severe COVID-19 patients were not 458 separated between who developed endothelial injury like RED PATIENTS from 459 those that developed cytokine storm characterized as PURPLE PATIENTs by the 460 461 peak of IL-6 followed by CRP. In these patients, their laboratory markers began to demonstrate worsening as a result of the MAS [23,58,62], or even a HLH 462 syndrome [13,18,21,63], prior to the clinical picture, which sometimes did not 463 464 manifest itself. Our findings are in agreement with Zuñiga and Moreno-Moral teams about high-dose corticosteroid pulse therapy in the increasing of the 465 survival rate of the COVID-19 patients at risk of hyper-inflammatory response 466 467 [64]. In addition, the pulse therapy would not be sufficient without broad-spectrum antibiotic therapy and the increased dose of cutaneous anticoagulant as reported 468 in several studies [19,21-23,55,58,63]. 469

470 Ferritin showed a peculiar behavior and was shown to be altered in some patients early in the first exams. Ferritin serves to carry and store iron for vital 471 472 cellular processes, while protecting against toxicity of this metal for the production of oxygen free radicals [22]. The follow-up of ferritin was very important because 473 a therapy to decrease the uptake and absorption of iron were given to the COVID-474 19 patients with increased ferritin early on. These patients were clinically well 475 despite having altered ferritin levels due to a pre-existing metabolic syndromes 476 477 [65,66]. However, this treatment had to be stopped in order not to mask the daily elevation and the increase close to the peak of IL-6 and CRP, as observed in 478 COVID-19 and in syndromes with hyperferritinemia [17,22,55,65,66]. The direct 479

role of ferritin in macrophage activation syndromes, such as COVID-19, lies in 480 481 the activation of macrophages that play a key role in the perpetuation of hyperferritinemia [17,22,55,65,66]. Herein, patients who had a cytokine storm 482 had an increase of 80 to 100% of ferritin related to the value of the previous day. 483 484 This fact makes us appreciate the importance of ferritin as an optimal marker of a cytokine storm, especially in those with an initial increase due to metabolic 485 syndrome, and that without prior treatment against absorption/uptake, this would 486 interfere with its reliability. 487

Our study also has some significant limitations. The drawbacks of the work were that, for some patients there are not all data of five markers daily, despite our efforts to perform the monitoring and dosing of five markers every day. That is due some patients did not present in the LEPAC or they were not found in their residences.

493 **Conclusions**

The home care follow-up was completely effective regardless of a first 494 consultation, or even without a tomographic image, as effective markers of 495 severity. The daily evaluation of the markers was important in order to classify 496 the severity at the onset of symptoms or even when the infection was 497 asymptomatic. CRP as a guide for the introduction of antibiotics, fibrinogen as a 498 guide for the introduction of anticoagulation therapy with enoxaparin and IL-6 as 499 a guide marker for the introduction of pulse therapy. Another observation of the 500 study was the inversion of IL-6 levels in relation to CRP levels to predict the 501 cytokine storm. Moreover, these observations led us to create a therapeutic 502 protocol associated with the clinical picture: This follow-up allowed the patients 503 to be subclassified into: (i) those whose antibiotic therapy was able to resolve the 504

SARS-Cov-2 infection, which was defined as YELLOW PATIENTs; (ii) those 505 506 whose infection presented endothelial injuries evidenced by increased fibrinogen and which was solved by a higher spectrum venous antibiotic therapy and 507 cutaneous anticoagulant defined here as RED PATIENTs; and (iii) the group of 508 509 patients with COVID-19 of greater severity in which patients developed a bacterial sepsis and viral response with the cytokine storm and which was resolved with 510 511 administration of a broad spectrum antibiotic therapy and pulse therapy with 512 dexamethasone and an increased dose of anticoagulant defined as PURPLE 513 PATIENTS.

514 Funding:

515 Rondônia State Health Department Budget.

516 Role of the Funder/Sponsor:

Neither the funder/sponsor of the study (the Rondônia State Health Department) had any role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Neither the funder nor the sponsor had any right to veto publication or to control the decision regarding to which journal the manuscript was submitted. All drafts of the manuscript were prepared by the authors.

524 Author Contributions

525 SPMMF, FSM and RHM conceived of the study and wrote the initial proposal. 526 SPMMF, FSM, RHM, SAB, LMAC contributed intellectually to the protocol 527 development. PAN estimated the sample size and performed all statistical 528 analysis. SPMMF, FSM, RHM, ABS and DCOM were the lead for the logistics

and data collection for the study. FSM, ABS, DCOM, PJG, ELO, JAL, YOC and 529 530 RSP actively reviewed all data from patients treated by the Multidisciplinary Home Medical Care Service. PJG, ELO, did the laboratory work. The initial draft of the 531 Article was written by PAN and SPMMF, who had full access to and verified all 532 the data underlying the study. All authors had access to the data, agreed to 533 submit for publication, and vouch for the integrity, accuracy, and completeness 534 535 of the data and for the fidelity of the patients' laboratory data. SPMMF, JPZ, RHM, LMCA and PAN contributed intellectually to the manuscript. All authors approved 536 the final submitted version. 537

538

539 Data sharing

540 Anonymized participant data can be made available upon requests directed to 541 the corresponding author. Proposals will be reviewed on the basis of scientific 542 merit. After approval of a proposal, data can be shared through a secure online 543 platform after signing a data access agreement.

544

545 **Conflict of Interest Disclosures**

The Healthy Secretariat of Rondônia State provided the costs for Multidisciplinary Home Care Service, supplies and medicines. The latter were provided by the Management and Pharmaceutical Assistance Coordination (CGAF). The State Laboratory of Pathologies and Clinical Analysis from Rondônia State (LEPAC) provided laboratory markers for monitoring patients during subsequent daily follow-up. All other authors declare no competing interests. 552

553 Acknowledgments

554 This study had a financial support from Healthy Secretariat of Rondônia State, Brazil. Laboratory supplies, collection supplies and related materials: Fundação 555 Oswaldo Cruz (Fiocruz) - INOVA: VPPCB-005-FIO-20-2-79 and FAPEAM 556 N⁰. PCTI-EMERGESAUDE Edital 006/2020 557 Programa (Number 01.02.016301.01078/2021). Projeto financiado com recursos do Programa de 558 Excelência em Pesquisa Básica e Aplicada em Saúde do Instituto Leônidas & 559 Maria Deane - ILMD/Fiocruz Amazônia - PROEP- LABS/ILMD FIOCRUZ 560 AMAZÔNIA We are grateful to all staff, particularly personnel from 561 Multidisciplinary Home Care Service who helped to monitoring and treating of 562 patients. Finally, we thank all of the participants, without whom this research 563 would not have been possible. 564

565

566 Legends

567

Figure 1. Kinetics of inflammatory markers in YELLOW PATIENTs. The
behavior of the markers in patients whose antibiotic therapy with amoxicillin
clavulanate was provided for 7 days. A) CRP levels during 16 days of follow up;
B) IL-6; C) Fibrinogen; D) The D-dimer; E) The ferritin curve in women; F) The
ferritin levels in men. Blue thin arrows indicate the beginning of antibiotic therapy.
The line represents the mean of data and gray area the standard deviation.

574

Figure 2. Kinetics of inflammatory markers in RED PATIENTs. The behavior
of the markers in patients treated with venous antibiotic and anticoagulant. A)
CRP levels during 16 days of follow up; B) IL-6; C) Fibrinogen; D) The D-dimer;
E) The ferritin curve in women; F) The ferritin levels in men. Blue thin arrows
indicate the beginning of antibiotic therapy. Red thin arrows indicate the
beginning of anticoagulant therapy. The line represents the mean of data and
gray area the standard deviation.

582

Figure 3. Kinetics of inflammatory markers in PURPLE PATIENTs. The 583 behavior of the markers in patients treated with venous antibiotic and 584 anticoagulant. A) CRP levels during 16 days of follow up; B) IL-6; C) Fibrinogen; 585 D) The D-dimer; E) The ferritin curve in women; F) The ferritin levels in men. Blue 586 thin arrows indicate the beginning of antibiotic therapy. Red thin arrows indicate 587 588 the beginning of anticoagulant therapy. Blue thick arrow indicates broadspectrum antibiotic therapy in order to prevent superinfections; Red thick arrow 589 indicates the increase in anticoagulation therapy with enoxaparin of 2 mg/kg day; 590 Green thick arrow indicates the pulse therapy due the inversion of IL-6 levels in 591 592 relation to CRP for the prediction of the cytokine storm. The line represents the mean of data and gray area the standard deviation. 593

594

Figure 4. Comparison of the kinetics of CRP and IL-6 in PURPLE and RED PATIENT groups. CRP and IL-6 kinetics allow distinguish the timing of the cytokine storm in PURPLE PATIENTS. Although the units of CRP and IL-6 are different, at the beginning of the disease in these two groups of patients are similar, though with the peak of CRP in mg/L being higher than the peak IL-6 in
pg/mL. The thick lines represent the mean of data and dashed lines the standard
deviation, RED the IL-6 kinetics and BLUE CRP kinetics. A) PURPLE PATIENTs;
B) RED PATIENTS.

603

Figure 5. The determination of therapy based on the dynamic of laboratory 604 markers. A) YELLOW PATIENTs had their infection resolved only with 605 antibiotics. These patients showed CRP alterations of between 5.0 and 20.0 and 606 607 IL-6 up to 30 pg/mL and received antibiotic therapy (ABT) of 875 mg amoxicillin and 125 mg potassium clavulanate every 12 h for 7 days. The other markers were 608 unaltered, and the infection was resolved in these patients. B) RED PATIENTS 609 showed increases in CRP levels to over 20 and IL-6 up to 30 pg/mL and 610 concomitant increases in fibrinogen to over 437. For the treatment of 611 612 opportunistic, ABT was replaced by 1 g of cefepime via venous route and 500mg 613 clarithromycin via oral route every 12 h, and patients received enoxaparin at 1 mg/kg/day subcutaneously for 7 days. C) PURPLE PATIENTs showed CRP 614 levels to over 20 and IL-6 up to 30 pg/mL and concomitant increases in fibrinogen 615 616 to over 437. For the treatment of opportunistic infections, ABT was replaced by 1 g of cefepime via venous route and 500mg clarithromycin via oral route every 12 617 h, and patients received enoxaparin at 1 mg/kg/day subcutaneously for 7 days. 618 619 CRP and IL-6 kinetics distinguished the timing of the cytokine storm with the peak IL-6 in pg/mL being higher than with the peak of CRP in mg/L. The pulse therapy 620 621 was given with dexamethasone 20 mg on Day 1, followed by 3 days at 10 mg/day and 3 days of 5 mg/day. They received an increase in the range of coverage of 622 antibiotics, with the addition of meropenem and amikacin, or tazobactam. The 623

627

628

629 References

- 1. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol.
- 631 2021;93: 250–256. doi:10.1002/jmv.26232
- 632 2. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-
- 19. Am J Pathol. 2021;191: 4–17. doi:10.1016/j.ajpath.2020.08.009
- Huang C, Wang Y, Li X, Ren L, Zhao J, Yi Hu LZ, et al. Clinical features
 of patients infected with 2019 novel coronavirus in Wuhan, China. J
- 636 Formos Med Assoc. 2020; 19–21.
- 4. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics
- of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382: 1708–
- 639 1720. doi:10.1056/nejmoa2002032
- 5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T,
- Davidson KW, et al. Presenting Characteristics, Comorbidities, and
- 642 Outcomes among 5700 Patients Hospitalized with COVID-19 in the New
- 643 York City Area. JAMA J Am Med Assoc. 2020;323: 2052–2059.
- 644 doi:10.1001/jama.2020.6775
- 645 6. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A
- 646 pneumonia outbreak associated with a new coronavirus of probable bat

- origin. Nature. 2020;579: 270–273. doi:10.1038/s41586-020-2012-7
- 648 7. Fouladseresht H, Doroudchi M, Rokhtabnak N, Abdolrahimzadehfard H,
- Roudgari A, Sabetian G, et al. Predictive monitoring and therapeutic
- immune biomarkers in the management of clinical complications of
- 651 COVID-19. Cytokine Growth Factor Rev. 2020.
- 652 doi:10.1016/j.cytogfr.2020.10.002
- 8. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S,
- Wang B, et al. An inflammatory cytokine signature predicts COVID-19
- 655 severity and survival. Nat Med. 2020;26: 1636–1643.
- 656 doi:10.1038/s41591-020-1051-9
- 9. Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview:
- 658 Systemic Inflammatory Response Derived From Lung Injury Caused by
- 659 SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Front

660 Immunol. 2020;11. doi:10.3389/fimmu.2020.01626

- 10. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383:
- 662 2255–2273. doi:10.1056/nejmra2026131
- 11. McGonagle D, Ramanan A V., Bridgewood C. Immune cartography of
- 664 macrophage activation syndrome in the COVID-19 era. Nat Rev
- 665 Rheumatol. 2021. doi:10.1038/s41584-020-00571-1
- 12. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19,
- 667 SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26:
- 668 729–734. doi:10.1016/j.cmi.2020.03.026 1198-743X
- 13. Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q,

670		et al. SARS-CoV-2 infection-Associated hemophagocytic
671		lymphohistiocytosis an autopsy series with clinical and laboratory
672		correlation. Am J Clin Pathol. 2020;154: 466–474.
673		doi:10.1093/AJCP/AQAA124
674	14.	Opoka-Winiarska V, Grywalska E, Roliński J. Could hemophagocytic
675		lymphohistiocytosis be the core issue of severe COVID-19 cases? BMC
676		Med. 2020;18: 1–11. doi:10.1186/s12916-020-01682-y
677	15.	Dimopoulos G, Mast Q De, Markou N, Lachana A, Veerdonk FL Van De,
678		Dimopoulos G, et al. Favorable Anakinra Responses in Severe Covid-19
679		Patients with Secondary Hemophagocytic Lymphohistiocytosis. Cell Host
680		Microbe. 2020;28: 117-123.e1. Available:
681		https://doi.org/10.1016/j.chom.2020.05.007
682	16.	Prieto-Pérez L, Fortes J, Soto C, Vidal-González Á, Alonso-Riaño M,
		Leferre M. et al. Histianutic hyperplacia with homopharapytania and cauta
683		Lafarga M, et al. Histiocytic hyperplasia with hemophagocytosis and acute
683 684		alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139–
684	17.	alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139–
684 685	17.	alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139– 2146. doi:10.1038/s41379-020-0613-1
684 685 686	17.	alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139– 2146. doi:10.1038/s41379-020-0613-1 Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic
684 685 686 687	17.	alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139– 2146. doi:10.1038/s41379-020-0613-1 Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a
684 685 686 687 688	17.	alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139– 2146. doi:10.1038/s41379-020-0613-1 Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report. J Med Case Rep. 2020;14: 1–5. doi:10.1186/s13256-020-
684 685 686 687 688 689		alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139– 2146. doi:10.1038/s41379-020-0613-1 Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report. J Med Case Rep. 2020;14: 1–5. doi:10.1186/s13256-020- 02503-9
684 685 686 687 688 689 690		alveolar damage in COVID-19 infection. Mod Pathol. 2020;33: 2139– 2146. doi:10.1038/s41379-020-0613-1 Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report. J Med Case Rep. 2020;14: 1–5. doi:10.1186/s13256-020- 02503-9 Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists'

19. Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. 694 695 HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1997;28: 342-347. doi:10.1002/(SICI)1096-696 911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H 697 20. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, 698 699 Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383: 1503-700 1516. doi:10.1016/S0140-6736(13)61048-X 21. Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G. 701 702 Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic 703 lymphohistiocytosis. J Pediatr. 2013;162: 1245–1251. 704 doi:10.1016/j.jpeds.2012.11.081 705 22. Moore C, Ormseth M, Fuchs H. Causes and significance of markedly 706 707 elevated serum ferritin levels in an academic medical center. J Clin Rheumatol. 2013;19: 324-328. doi:10.1097/RHU.0b013e31829ce01f 708 23. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine 709 Storm' in COVID-19. J Infect. 2020;80: 607-613. 710 711 24. Auyeung TW, Lee JSW, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use 712 of corticosteroid as treatment in SARS was associated with adverse outcomes: A retrospective cohort study. J Infect. 2005;51: 98–102. 713 doi:10.1016/j.jinf.2004.09.008 714 715 25. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, et al. High-Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute 716 717 Respiratory Syndrome. Am J Respir Crit Care Med. 2003;168: 1449718

1456. doi:10.1164/rccm.200306-766OC

Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia 719 26. and Its Association with Mortality in Patients with COVID-19.pdf. J 720 721 Thromb Haemost. 2020. doi:10.1111/jth.14848. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 722 27. patients. Ann Hematol. 2020. doi:10.1007/s00277-020-04019-0 723 724 28. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. 2020;38: 22-725 24. 726 Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, 727 29. biochemical and immune biomarker abnormalities associated with severe 728 illness and mortality in coronavirus disease 2019 (COVID-19): a meta-729 analysis. Clin Chem Lab Med. 2020. doi:10.1515/cclm-2020-0369 730 731 30. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 732 733 patients with coagulopathy. J Thromb Haemost. 2020. doi:10.1111/jth.14817 734 735 31. Ranucci M, Ballotta A, Dedda U Di, Bayshnikova E, Poli MD, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory 736 distress syndrome. J Thromb Haemost. 2020. doi:10.1111/ith.14854 737 Vinayagam S, Kamaraj Sattu. SARS-CoV-2 and coagulation disorders in 738 32. different organs. Life Sci J. 2020;260: 118431. 739 740 33. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus

741		infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from					
742		the past. J Clin Virol. 2020;127. doi:10.1016/j.jcv.2020.104362					
743	34.	Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Asso					
744		with Acute Respiratory Distress Syndrome and Death in Patients with					
745		Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern					
746		Med. 2020; 1–10. doi:10.1001/jamainternmed.2020.0994					
747	35.	Chertow DS, Memoli MJ. Bacterial coinfection in influenza: A grand					
748		rounds review. JAMA - J Am Med Assoc. 2013;309: 275–282.					
749		doi:10.1001/jama.2012.194139					
750	36.	Morens DM, Taubenberger JK, Fauci AS. Predominant Role of Bacterial					
751		Pneumonia as a Cause of Death in Pandemic Influenza: Implications for					
752		Pandemic Influenza Preparedness. J Infect Dis. 2008;198: 962–70.					
753		doi:10.1086/591708.Predominant					
754	37.	Langford BJ, So M, Raybardhan S, Leung V, Westwood D, Macfadden					
755		DR, et al. Bacterial co-infection and secondary infection in patients with					
756		COVID- 19: a living rapid review and meta-analysis. Clin Microbiol Infect.					
757		2020;26: 1622–1629.					
758	38.	Van Der Meer V, Neven AK, Van Den Broek PJ, Assendelft WJJ.					
759		Diagnostic value of C reactive protein in infections of the lower respiratory					
760		tract: Systematic review. Br Med J. 2005;331: 26–29.					
761		doi:10.1136/bmj.38483.478183.EB					
762	39.	Oung B, Leeson M, Crippss A. C-reactive protein: a critical review. 1991;					
763		118–124.					

764	40.	Do NTT, Greer RC, Lubell Y, Dittrich S, Vandendorpe M, Nguyen VA, et
765		al. Implementation of C-reactive protein point of care testing to improve
766		antibiotic targeting in respiratory illness in Vietnamese primary care
767		(ICAT): A study protocol for a cluster randomised controlled trial. BMJ
768		Open. 2020;10: 1–9. doi:10.1136/bmjopen-2020-040977
769	41.	Aabenhus R, Jensen JUS, Jørgensen KJ, Hróbjartsson A, Bjerrum L.
770		Biomarkers as point-of-care tests to guide prescription of antibiotics in
771		patients with acute respiratory infections in primary care. Cochrane
772		Database Syst Rev. 2014;2014. doi:10.1002/14651858.CD010130.pub2
773	42.	Pal R, Banerjee M, Bhadada SK, Shetty AJ, Singh B, Vyas A. Vitamin D
774		supplementation and clinical outcomes in COVID-19: a systematic review
775		and meta-analysis. J Endocrinol Invest. 2021. doi:10.1007/s40618-021-
//3		
776		01614-4
	43.	
776	43.	01614-4
776 777	43.	01614-4 Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential
776 777 778	43. 44.	01614-4 Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019. Futur microbiol,. 2020; 10–
776 777 778 779		01614-4 Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019. Futur microbiol,. 2020; 10– 13. Available: https://dx.doi.org/10.2217/fmb-2020-0074
776 777 778 779 780		01614-4 Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019. Futur microbiol,. 2020; 10– 13. Available: https://dx.doi.org/10.2217/fmb-2020-0074 Grotto HZW. Fisiologia e metabolismo do ferro. Rev Bras Hematol
776 777 778 779 780 781	44.	01614-4 Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019. Futur microbiol,. 2020; 10– 13. Available: https://dx.doi.org/10.2217/fmb-2020-0074 Grotto HZW. Fisiologia e metabolismo do ferro. Rev Bras Hematol Hemoter. 2010;32: 8–17. doi:10.1590/S1516-84842010005000050
776 777 778 779 780 781 782	44.	01614-4 Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019. Futur microbiol,. 2020; 10– 13. Available: https://dx.doi.org/10.2217/fmb-2020-0074 Grotto HZW. Fisiologia e metabolismo do ferro. Rev Bras Hematol Hemoter. 2010;32: 8–17. doi:10.1590/S1516-84842010005000050 Merad M, Martin JC. Pathological inflammation in patients with COVID-
776 777 778 779 780 781 782 783	44.	01614-4 Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019. Futur microbiol,. 2020; 10– 13. Available: https://dx.doi.org/10.2217/fmb-2020-0074 Grotto HZW. Fisiologia e metabolismo do ferro. Rev Bras Hematol Hemoter. 2010;32: 8–17. doi:10.1590/S1516-84842010005000050 Merad M, Martin JC. Pathological inflammation in patients with COVID- 19: a key role for monocytes and macrophages. Nat Rev Immunol.

787	47.	Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med.						
788		2020;383: 2451–2460. doi:10.1056/nejmcp2009575						
789	48.	Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N Engl J						
790		Med. 2020; 1–9. doi:10.1056/nejmcp2009249						
791	49.	Robin Patel, Babady E, Theel ES, Storch GA, Pinsky BA, George K St., et						
792		al. Report from the American Society for Microbiology COVID-19 COVID-						
793		19. MBio. 2020;11: e00722-20. doi:DOI: 10.1128/mBio.00722-20						
794	50.	Seaton RA, Gibbons CL, Cooper L, Malcolm W, Mckinney R, Dundas S,						
795		et al. Survey of antibiotic and antifungal prescribing in patients with						
796		suspected and confirmed COVID-19 in Scottish hospitals. 2020.						
797	51.	Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE,						
798		Aleva RM, et al. Recommendations for antibacterial therapy in adults with						
799		COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021;27:						
800		61–66. doi:10.1016/j.cmi.2020.09.041						
801	52.	Langford BJ, So M, Raybardhan S, Leung V, Westwood D, Macfadden						
802		DR, et al. Bacterial co-infection and secondary infection in patients with						
803		COVID- 19: a living rapid review and meta-analysis. Clin Microbiol Infect.						
804		2020;26.						
805	53.	Vinayagam S, D KSP. SARS-CoV-2 and coagulation disorders in different						
806		organs. Life Sci J. 2020;260: 118431.						
807	54.	Muiños PJA, Otero DL, Amat-Santos IJ, País JL, Aparisi A, Antonio CEC,						
808		et al. The COVID-19 lab score.pdf. Sci Rep. 2021;11.						
809	55.	Alunno A, Carubbi F, Rodríguez-Carrio J. Storm, typhoon, cyclone or						


810		hurricane in patients with COVID-19? Beware of the same storm that has
811		a different origin. RMD Open. 2020;6: 1-4. doi:10.1136/rmdopen-2020-
812		001295
813	56.	Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et
814		al. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
815		Arthritis and Rheumatology. 2020. pp. 1059–1063. doi:10.1002/art.41285
816	57.	Haigh K, Joanna Z, Irvine S, Blanchard TJ, Sajid M, Toth AG, et al.
817		Hyperinflammation with COVID-19: The key to patient deterioration? Clin
818		Infect Pract. 2020;7–8: 100033.
819	58.	Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S.
820		Cytokine storm in COVID-19: pathogenesis and overview of anti-
821		inflammatory agents used in treatment. Clin Rheumatol. 2020;39: 2085-
822		2094. doi:10.1007/s10067-020-05190-5
823	59.	Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
824		corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:
825		473–475. doi:10.1016/S0140-6736(20)30317-2
826	60.	The_RECOVERY_Collaborative Group. Dexamethasone in Hospitalized
827		Patients with Covid-19 — Preliminary Report. N Engl J Med. 2020; 1–11.
828		doi:10.1056/nejmoa2021436
829	61.	The_RECOVERY_Collaborative_Group. Colchicine in patients admitted
830		to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
831		label, platform trial. Lancet Respir Med. 2021;9: 1419–1426.
832		doi:10.1016/S2213-2600(21)00435-5


833	62.	Mcgonagle D, Sharif K, Regan AO, Bridgewood C. The Role of Cytokines
834		including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage
835		Activation Syndrome-Like Disease. Autoimmun Rev J. 2020;19: 102537.
836	63.	Histiocyte Society. Recommendations and Considerations from the
837		Histiocyte Society During the Evaluation of Hospitalized COVID-19
838		Patients for Hyperinflammation. In: Journal of Chemical Information and
839		Modeling [Internet]. 2020. Available:
840		https://histiocytesociety.wildapricot.org/resources/Documents/HS COVID-
841		19 Statement - FINAL.pdf
842	64.	Zúñiga MÁL, Moreno-Moral A, Ocaña-Granados A, Padilla-Moreno FA,
843		Castillo-Fernández AM, Guillamón-Fernández D, et al. High-dose
844		corticosteroid pulse therapy increases the survival rate in COVID-19
845		patients at risk of hyper-inflammatory response. PLoS One. 2021;16: 1-
846		13. doi:10.1371/journal.pone.0243964
847	65.	Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg
848		D, et al. Marked hyperferritinemia does not predict for HLH in the adult
849		population. Blood. 2015;125: 1548–1552. doi:10.1182/blood-2014-10-
850		602607
851	66.	Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: A
852		new character in the spectrum of the hyperferritinemic syndrome?
853		Autoimmun Rev. 2020;19: 102573. doi:10.1016/j.autrev.2020.102573
854		


	CONTROL N=27	BLUE PATIENT N=33	YELLOW PATIENT N=28	RED PATIENT N=23	PURPLE PATIENT N=32	р
gender (% male). χ2	44.4	48.5	32.1	43.5	71.9 *	0.0343
age	35 (24.2 ; 42.2) ^a	33 (26.5 ; 44.5) ^a	40 (33.0 ; 48.5) ^{ab}	44.5 (35.2 ; 54) ^{ab}	46 (39.7 ; 62) ^b	0.0002
Hematocrit	38 (36.18 ; 40.15)	39.35 (38.75 ; 41.58)	38.8 (37.05 ; 41.9)	37.8 (35.9 ; 40.35)	43.6 (37.35 ; 46)	0.0562
Hemoglobin	13.5 (12.28 ; 14.2)	13.8 (12.93 ; 14.8)	13.75 (12.7 ; 15)	13.2 (12.05 ; 13.88)	15.1 (12.6 ; 16.4)	0.0952
Red Blood cells	4.4 (4.245 ; 4.988)	4.71 (4.46 ; 5.04)	4.925 (4.485 ; 115.7)	4.66 (4.433 ; 304.3)	5.1 (4.55 ; 5.325)	0.0936
VCM	84.75 (83.35 ; 87.65)	85.5 (82.73 ; 87.48)	85.2 (82.35 ; 87.53)	85.1 (82.88 ; 88.23)	87.3 (83.8 ; 88.5)	0.7592
HCM	29.95 (28.65 ; 30.9)	29.45 (28.28 ; 30.83)	29.65 (28.95 ; 30.35)	29.45 (27.68 ; 30.3)	30.4 (28 ; 31.7)	0.7404
CHCM	35.05 (34.3 ; 35.53)	34.9 (33.35 ; 35.53)	34.45 (33.95 ; 34.93)	34.35 (33.7 ; 35.28)	34.3 (32.95 ; 35.65)	0.4266
Leukocytes	7400 (6675 ; 9060)	6635 (5253 ; 9833)	6035 (3340 ; 7853)	6485 (5060 ; 9638)	7870 (5850 ; 9670)	0.1909
Eosinophils	147.4 (81.7 ; 381.2)	133.9 (63.95 ; 212.9)	83.3 (0 ; 242.2)	57.7 (0 ; 136.1)	138.0 (80 ; 270.6)	0.0670
Neutrophils	4056 (2698 ; 4829)	3396 (1778 ; 5002)	2816 (1490 ; 4486)	3893 (3083 ; 6118)	5180 (3293 ; 6705)	0.1064
Lymphocytes	2172 (1492 ; 2755)	2315 (1216 ; 2906)	2045 (1650 ; 2689)	1928 (1518 ; 2640)	1754 (1224 ; 2640)	0.8516
Monocytes	427 (311.6 ; 621.3)	426.7 (197.7 ; 627.1)	407.4 (271 ; 642.2)	554.4 (320 ; 624.8)	483 (205.7 ; 646.4)	0.9063
Platelets	243500 (173750 ; 333250)	252000 (209500 ; 315250)	226500 (186250 ; 273250)	252500 (181750 ; 290000)	219000 (166500 ; 294000)	0.4995
Neu/Lymp ratio	1.902(1.404 ; 3.007) ^{ab}	1.53(1.225;3.074) ^{ab}	1.27 (0.8698 ; 1.922) ^a	1.813(1.444 ; 3.295) ^{ab}	2.957 (1.339 ; 3.652) ^b	0.0153
Lymp/Mono ratio	4.5 (3.216 ; 5.544)	5 (3.833 ; 6.25)	5.3 (3.771 ; 6.167)	4.4 (2.888 ; 5.065)	4.25 (2.795 ; 6.875)	0.4992
PLT/Lymp ratio	109.7 (79.41 ; 174.7)	124.2 (82.05 ; 182.7)	103.1 (93.33 ; 130.8)	125.3 (100.7 ; 153.9)	118.4 (76.33 ; 155.1)	0.8079
urea	22.4 (20.05 ; 30.25)	23.6 (20.33 ; 31.68)	22.2 (18.5 ; 26.6)	25.3 (18.1 ; 32.28)	36.4 (21.5 ; 38.9)	0.1946
creatinine	0.9 (0.6225 ; 1.045)	0.9 (0.745 ; 1.135)	0.8 (0.765 ; 1.103)	0.7 (0.6125 ; 0.925)	0.9 (0.82 ; 1.075)	0.1223
sodium	140.5 (138 ; 141.5)	137.0 (134.8 ; 141.3)	140.0 (139 ; 141)	139.5 (138 ; 141.5)	138.5 (135.5 ; 141.5)	0.2044
potassium	3.9 (3.668 ; 4.173)	3.8 (3.798 ; 4.423)	3.9 (3.645 ; 4.255)	4.0 (3.94 ; 4.38)	4.0 (3.833 ; 4.453)	0.7590
TGO	19.5 (15.75 ; 26.25)	22.0 (19 ; 30)	30.0 (19.45 ; 60.5)	31.0 (19 ; 60.25)	22.0 (18 ; 29)	0.0464
TGP	17.5 (12 ; 28.5) [°]	26.0 (15 ; 48) ^{ab}	32.3 (19 ; 67.25) ^{ab}	36.5 (21 ; 74) ^b	29.0 (22 ; 40.5) ^{ab}	0.0445


Table 1. Biochemical and hematological parameters in the first examination


Median (25; 75 interquartiles). Anova Kruskal Wallis and Dunn's multiple comparisons test























D


F


В

















В

